• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by ADMA Biologics Inc

    10/17/24 9:22:50 AM ET
    $ADMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ADMA alert in real time by email
    SC 13G 1 ADMA_Biologics_Inc.htm SCHEDULE 13G Amendment No. 15

     

      SECURITIES AND EXCHANGE COMMISSION  
      Washington, D.C. 20549  
     
    SCHEDULE 13G
     
     
    Under the Securities Exchange Act of 1934
     
    (Amendment No. )*
     

    ADMA BIOLOGICS INC

    (Name of Issuer)
     

    COMMON STOCK

    (Title of Class of Securities)
     

    000899104

    (CUSIP Number)
     

    September 30, 2024

    (Date of Event Which Requires Filing of This Statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
    ý Rule 13d-1(b)
    ¨ Rule 13d-1(c)
    ¨ Rule 13d-1(d)
     
    (Page 1 of 5 Pages)

     

    ______________________________

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

     

    000899104 13G Page 2 of 5 Pages

     

    1

    NAME OF REPORTING PERSON

    STATE STREET CORPORATION

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON: 04-2456637

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    MA

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH: 5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    12,203,756

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    13,004,993

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    13,004,993.00

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    5.6%

    12

    TYPE OF REPORTING PERSON

    HC

             

     

     

     

    000899104 13G Page 3 of 5 Pages

     

    Item 1(a). NAME OF ISSUER
       
      ADMA BIOLOGICS INC

     

    Item 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES
       
      465 ROUTE 17 SOUTH RAMSEY NJ 07446 UNITED STATES

     

    Item 2(a). NAME OF PERSON FILING
       
     

    STATE STREET CORPORATION

     

    Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE
       
      ONE CONGRESS STREET, SUITE 1, BOSTON MA 02114, UNITED STATES

     

    Item 2(c). CITIZENSHIP
       
      MA

     

    Item 2(d). TITLE OF CLASS OF SECURITIES
       
      COMMON STOCK

     

    Item 2(e). CUSIP NUMBER
       
      000899104

     

    Item 3. IF THIS STATEMENT IS FILED PURSUANT TO §§240.13d-1(b), OR 13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:

     

    STATE STREET CORPORATION (a) Broker or dealer registered under Section 15 of the Act;
      (b) Bank as defined in Section 3(a)(6) of the Act;
      (c) Insurance company as defined in Section 3(a)(19) of the Act;
      (d) Investment company registered under Section 8 of the Investment Company Act of 1940;
      (e) An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
      (f)

    An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

     

      (g) X

    A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);

     

      (h)

    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;

     

      (i)

    A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;

     

      (j) A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
      (k) Group, in accordance with §240.13d-1(b)(1)(ii)(K).
      If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:

     

     

    000899104 13G Page 4 of 5 Pages

     

    Item 4. OWNERSHIP
       
      Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
      (a) Amount beneficially owned: 13,004,993.00  
      (b) Percent of class: 5.6%  
      (c) Number of shares as to which the person has:    
             
        (i) Sole power to vote or to direct the vote: 0
        (ii) Shared power to vote or to direct the vote 12,203,756
        (iii) Sole power to dispose or to direct the disposition of 0
        (iv) Shared power to dispose or to direct the disposition of 13,004,993
             
      Instruction. For computations regarding securities which represent a right to acquire an underlying security see §240.13d-3(d)(1).

     

    Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following
      ¨
      Instruction: Dissolution of a group requires a response to this item.

     

    Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON
       
      NOT APPLICABLE

     

    Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY OR CONTROL PERSON
       
      SSGA FUNDS MANAGEMENT, INC. (IA) STATE STREET GLOBAL ADVISORS EUROPE LIMITED (IA) STATE STREET GLOBAL ADVISORS LIMITED (IA) STATE STREET GLOBAL ADVISORS TRUST COMPANY (IA) STATE STREET GLOBAL ADVISORS, AUSTRALIA, LIMITED (IA) STATE STREET GLOBAL ADVISORS, LTD. (IA)

     

    Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP
       
      NOT APPLICABLE

     

    Item 9. NOTICE OF DISSOLUTION OF GROUP
       
      NOT APPLICABLE

     

    Item 10. CERTIFICATION

     

      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11
       

     

     

     

    000899104 13G Page 5 of 5 Pages

     

    SIGNATURES

    After reasonable inquiry and to the best of its knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

    DATE: October 14, 2024

     

       
         
         
        ELIZABETH SCHAEFER, SENIOR VICE PRESIDENT, CHIEF ACCOUNTING OFFICER
         
         

     

    The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

     

    NOTE: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties for whom copies are to be sent.

     

    Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001)

     

    Get the next $ADMA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ADMA

    DatePrice TargetRatingAnalyst
    7/19/2023$5.00Strong Buy
    Raymond James
    10/13/2022$5.00Buy
    Mizuho
    11/11/2021$5.00Outperform → Strong Buy
    Raymond James
    11/9/2021$4.50Overweight
    Cantor Fitzgerald
    10/26/2021$6.00 → $5.00Outperform
    Raymond James
    8/12/2021$7.00 → $6.00Buy
    HC Wainwright & Co.
    7/6/2021$10.00 → $7.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $ADMA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by ADMA Biologics Inc

      SC 13G/A - ADMA BIOLOGICS, INC. (0001368514) (Subject)

      11/12/24 1:34:17 PM ET
      $ADMA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by ADMA Biologics Inc

      SC 13G - ADMA BIOLOGICS, INC. (0001368514) (Subject)

      11/8/24 9:21:37 AM ET
      $ADMA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by ADMA Biologics Inc

      SC 13G - ADMA BIOLOGICS, INC. (0001368514) (Subject)

      11/4/24 11:00:41 AM ET
      $ADMA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ADMA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • ADMA Biologics Announces First Quarter 2025 Financial Results and Provides Business Update

      1Q 2025 Total Revenue of $114.8 Million (Adjusted Total Revenue(1) of $118.6 Million), a 40% YoY Increase 1Q 2025 GAAP Net Income of $26.9 Million, a 51% YoY Increase 1Q 2025 Adjusted EBITDA(2) of $47.9 Million, an 81% YoY Increase 1Q 2025 Adjusted Net Income(3) of $33.3 Million, an 87% YoY Increase 1Q 2025 Total Cash and Receivables Grew to Approximately $171 Million FDA Approved Yield Enhancement Process Anticipated to Provide 20% Production Output Enhancement from Same Starting Plasma Volume, and Support Revenue Growth and Margin Expansion Opportunity FY 2025 and 2026 Total Revenue Guidance Increased to More than $500 Million and $625 Million, Respectively FY 2025 Adjusted Net In

      5/7/25 4:05:00 PM ET
      $ADMA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • ADMA Biologics to Report First Quarter 2025 Financial Results on May 7, 2025

      RAMSEY, N.J. and BOCA RATON, Fla., April 30, 2025 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA" or the "Company"), a U.S. based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty biologics, today announced that it will report first quarter 2025 financial results on May 7, 2025, after the U.S. financial markets close. ADMA's management team will host a live conference call and audio webcast on that date at 4:30 p.m. ET to discuss its financial results and other Company updates. To access the conference call seamlessly, participants are required to register for the call here to receive the dial-in numbers and uni

      4/30/25 7:00:00 AM ET
      $ADMA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • ADMA Biologics Announces U.S. FDA Approval of Innovative Production Yield Enhancement Process

      Approval Supports Revenue Growth and Margin Expansion Opportunity, and Substantially Increases Peak Production Output Capacity First U.S. Regulatory Approval of Innovative IG Yield Enhancement Process Highlights ADMA's Uniquely Efficient Internal R&D Engine, Spanning Production and Product Development Capabilities Anticipate Approximately 20% Production Output Enhancement from Same Starting Plasma Volume The 20% Yield Enhancement Will Benefit Both ASCENIV and BIVIGAM RAMSEY, N.J. and BOCA RATON, Fla., April 28, 2025 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA" or the "Company"), a U.S. based, end-to-end commercial biopharmaceutical company dedicated to manufacturing,

      4/28/25 7:00:00 AM ET
      $ADMA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ADMA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Raymond James resumed coverage on ADMA Biologics with a new price target

      Raymond James resumed coverage of ADMA Biologics with a rating of Strong Buy and set a new price target of $5.00

      7/19/23 9:02:26 AM ET
      $ADMA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Mizuho initiated coverage on ADMA Biologics with a new price target

      Mizuho initiated coverage of ADMA Biologics with a rating of Buy and set a new price target of $5.00

      10/13/22 7:18:25 AM ET
      $ADMA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • ADMA Biologics upgraded by Raymond James with a new price target

      Raymond James upgraded ADMA Biologics from Outperform to Strong Buy and set a new price target of $5.00

      11/11/21 6:21:44 AM ET
      $ADMA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ADMA
    SEC Filings

    See more
    • SEC Form SCHEDULE 13G filed by ADMA Biologics Inc

      SCHEDULE 13G - ADMA BIOLOGICS, INC. (0001368514) (Subject)

      5/9/25 4:14:39 PM ET
      $ADMA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by ADMA Biologics Inc

      10-Q - ADMA BIOLOGICS, INC. (0001368514) (Filer)

      5/7/25 5:15:53 PM ET
      $ADMA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • ADMA Biologics Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits

      8-K - ADMA BIOLOGICS, INC. (0001368514) (Filer)

      5/7/25 4:12:24 PM ET
      $ADMA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ADMA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President and CEO Grossman Adam S exercised 15,000 shares at a strike of $5.40 and sold $450,660 worth of shares (21,000 units at $21.46), decreasing direct ownership by 0.29% to 2,055,850 units (SEC Form 4)

      4 - ADMA BIOLOGICS, INC. (0001368514) (Issuer)

      4/16/25 9:00:26 PM ET
      $ADMA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • COO and SVP, Compliance Kestenberg-Messina Kaitlin M. covered exercise/tax liability with 18,920 shares, decreasing direct ownership by 4% to 490,425 units (SEC Form 4)

      4 - ADMA BIOLOGICS, INC. (0001368514) (Issuer)

      4/2/25 9:00:38 PM ET
      $ADMA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • President and CEO Grossman Adam S exercised 15,000 shares at a strike of $5.40 and sold $397,320 worth of shares (21,000 units at $18.92), decreasing direct ownership by 0.29% to 2,061,850 units (SEC Form 4)

      4 - ADMA BIOLOGICS, INC. (0001368514) (Issuer)

      3/21/25 9:00:15 PM ET
      $ADMA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ADMA
    Financials

    Live finance-specific insights

    See more
    • ADMA Biologics Announces First Quarter 2025 Financial Results and Provides Business Update

      1Q 2025 Total Revenue of $114.8 Million (Adjusted Total Revenue(1) of $118.6 Million), a 40% YoY Increase 1Q 2025 GAAP Net Income of $26.9 Million, a 51% YoY Increase 1Q 2025 Adjusted EBITDA(2) of $47.9 Million, an 81% YoY Increase 1Q 2025 Adjusted Net Income(3) of $33.3 Million, an 87% YoY Increase 1Q 2025 Total Cash and Receivables Grew to Approximately $171 Million FDA Approved Yield Enhancement Process Anticipated to Provide 20% Production Output Enhancement from Same Starting Plasma Volume, and Support Revenue Growth and Margin Expansion Opportunity FY 2025 and 2026 Total Revenue Guidance Increased to More than $500 Million and $625 Million, Respectively FY 2025 Adjusted Net In

      5/7/25 4:05:00 PM ET
      $ADMA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • ADMA Biologics to Report First Quarter 2025 Financial Results on May 7, 2025

      RAMSEY, N.J. and BOCA RATON, Fla., April 30, 2025 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA" or the "Company"), a U.S. based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty biologics, today announced that it will report first quarter 2025 financial results on May 7, 2025, after the U.S. financial markets close. ADMA's management team will host a live conference call and audio webcast on that date at 4:30 p.m. ET to discuss its financial results and other Company updates. To access the conference call seamlessly, participants are required to register for the call here to receive the dial-in numbers and uni

      4/30/25 7:00:00 AM ET
      $ADMA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • ADMA Biologics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

      FY 2024 Total Revenue of $426.5 Million, a 65% YoY Increase FY 2024 GAAP Net Income of $197.7 Million, Including an $84.3 Million Valuation Allowance Tax Benefit FY 2024 Adjusted EBITDA(1) of $164.6 Million, a 309% YoY Increase FY 2024 Adjusted Net Income(2) of $119.2 Million, Compared to $0.7 Million in FY 2023, a 16,810% YoY Increase YE 2024 Total Cash Grew to More than $103 Million, Including $60 Million of Debt Organically Discharged During 2H 2024 High-Titer Plasma Supply Contracts Expected to Provide Foundation for Durable ASCENIV Revenue Growth Through Late 2030s FDA Approval of Yield Enhancement Production Process Anticipated by Mid-2025

      3/3/25 4:05:00 PM ET
      $ADMA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ADMA
    Leadership Updates

    Live Leadership Updates

    See more
    • ADMA Biologics Set to Join S&P SmallCap 600 Index

      RAMSEY, N.J. and BOCA RATON, Fla., Sept. 17, 2024 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA"), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty biologics, today announced it will join the S&P SmallCap 600 index, effective prior to the open of trading on Monday, September 23, 2024. The S&P SmallCap 600 seeks to measure the small-cap segment of the U.S. equity market. "ADMA's inclusion in the S&P SmallCap 600 index is a significant milestone for our company," Adam Grossman, President and Chief Executive Officer of ADMA. "We expect this inclusion will increase our visibility within the investment communit

      9/17/24 7:00:00 AM ET
      $ADMA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Palantir Technologies, Dell Technologies, and Erie Indemnity Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

      NEW YORK, Sept. 6, 2024 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, September 23, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P SmallCap 600 are more representative of the small-cap market space. The companies being removed from

      9/6/24 6:43:00 PM ET
      $AAL
      $ADMA
      $ADNT
      $AMCX
      Air Freight/Delivery Services
      Consumer Discretionary
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • ADMA Biologics Strengthens its Board of Directors with the Appointment of Young T. Kwon, Ph.D.

      RAMSEY, N.J. and BOCA RATON, Fla., Oct. 18, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA" or the "Company"), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced the appointment of Young T. Kwon, Ph.D., to its Board of Directors. Dr. Kwon is a highly accomplished corporate executive in the life sciences and biotechnology space. He brings over a decade of expertise in strategic advising, corporate finance and business development transactions to ADMA's Board. "Young is a recognized leader in the healthcare sector and his deep strategic and financial experience

      10/18/21 7:00:00 AM ET
      $ADMA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care